

410 PCT/PTO 30 JUN 2000

| | | | |
|--|---|---|---|
| FORM PTD-1390 | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTORNEY'S DOCKET NUMBER 10806-129 |
| TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 | | | U.S. APPLIC. NO. (if known, see 37 CFR 1.5) 09/582734 |
| INTERNATIONAL APPLICATION NO. PCT/SE98/02463 | INTERNATIONAL FILING DATE 30 DECEMBER 1998 | PRIORITY DATE CLAIMED 30 DECEMBER 1997 | |
| TITLE OF INVENTION ANALYTICAL METHOD COMPRISING ADDITION IN TWO OR MORE POSITIONS AND A DEVICE OR TEST KIT THEREFOR | | | |
| APPLICANT(S) FOR DO/EO/US MENDEL-HARTVIG, Ib; ZELIKMAN, Ilya; RUNDSTRÖM, Gerd | | | |
| Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: | | | |
| 1. [X] This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. | | | |
| 2. [] This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. | | | |
| 3. [X] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). | | | |
| 4. [X] A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. | | | |
| 5. [X] A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. [] is transmitted herewith (required only if not transmitted by the International Bureau). b. [X] has been transmitted by the International Bureau (22 July 1999). c. [] is not required, as the application was filed in the United States Receiving Office (RO/US) | | | |
| 6. [] A translation of the International Application into English (35 U.S.C. 371(c)(2)). | | | |
| 7. [X] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. [] are transmitted herewith (required only if not transmitted by the International Bureau). b. [] have been transmitted by the International Bureau. c. [] have not been made; however, the time limit for making such amendment has NOT expired. d. [X] have not been made and will not be made. | | | |
| 8. [] A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). | | | |
| 9. [] An oath or declaration of the inventor(s) (35 U.S.C. 371(d)(4)). | | | |
| 10. [] A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). | | | |
| Items 11. to 16. below concern other document(s) or information included: | | | |
| 11. [] An Information Disclosure Statement under 37 CFR 1.97 and 1.98. | | | |
| 12. [] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. | | | |
| 13. [X] A FIRST preliminary amendment. [] A SECOND or SUBSEQUENT preliminary amendment. | | | |
| 14. [] A substitute specification. | | | |
| 15. [] A change of power of attorney and/or address letter. | | | |
| 16. [X] Other items or information: Copy of published International application, including Search Report | | | |

CERTIFICATE OF EXPRESS MAILING

"Express Mail" mailing label #: EL343337399US

Date of Deposit: 30 June 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Box PCT; Assistant Commissioner for Patents; Washington, DC 20231.

Catherine J. Vagin

| | | |
|---|---|---------------------------------------|
| U.S. APPLIC. NO. (if known) 37 CFR 1.50) 09/582734 | INTERNATIONAL APPLICATION NO. PCT/SE98/02463 | ATTORNEY'S DOCKET NUMBER 10806-129 |
|---|---|---------------------------------------|

| | | |
|--|---------------------|--------------|
| | CALCULATIONS | PTO USE ONLY |
|--|---------------------|--------------|

17. The following fees are submitted:

| | |
|--|----------|
| <input type="checkbox"/> Basic National Fee (37 CFR 1.492(a)(1)-(5)): | |
| <input type="checkbox"/> Search Report has been prepared by the EPO or JPO | \$840.00 |
| <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) | \$670.00 |
| <input type="checkbox"/> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) | \$760.00 |
| <input checked="" type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO | \$970.00 |
| <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) | \$96.00 |

ENTER APPROPRIATE BASIC FEE AMOUNT =

| | |
|--|-----------|
| Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)). | \$ 130.00 |
|--|-----------|

| Claims | Number Filed | Number Extra | Rate | |
|---|--------------|--------------|------------|-----------|
| Total Claims | 33 -20 = | 13 | x \$18.00 | \$ 234.00 |
| Independent Claims | 3 -3 = | 0 | x \$78.00 | \$ |
| Multiple dependent claim(s) (if applicable) | | | + \$260.00 | \$ |

TOTAL OF ABOVE CALCULATIONS =

| | |
|--|-----------|
| Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28). | \$ |
| SUBTOTAL = | \$1334.00 |

Processing fee of \$130.00 for furnishing the English translation later than the ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).

| | |
|-----------------------------|-----------|
| TOTAL NATIONAL FEE = | \$1334.00 |
|-----------------------------|-----------|

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property

| | |
|------------------------------|-----------|
| TOTAL FEES ENCLOSED = | \$1334.00 |
|------------------------------|-----------|

| | |
|--|------------------|
| | Amount to be: \$ |
| | refunded |
| | charged \$ |


a. ☒ A check in the amount of \$1,334.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 04-1133.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

| | |
|---|---|
| Holly D. Kozlowski DINSMORE & SHOHL 1900 Chemed Center 295 East Fifth Street Cincinnati, Ohio 45202 (513) 977-8200 | SIGNATURE  HOLLY D. KOZLOWSKI NAME 30.468 REGISTRATION NUMBER 30 JUNE 2000 DATE |
|---|---|

Docket No. 10806-129

CERTIFICATE OF MAILING

"Express Mail" mailing label #: EL343337399US

Date of Deposit: June 30, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Box PCT; Assistant Commissioner for Patents; Washington, DC 20231.

Catharine L. Vigil

PATENT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Ib MENDEL-HARTVIG et al : Paper No.:
Based On: PCT/SE98/02463 : Group Art Unit:
Filing Date: June 30, 2000 : Examiner:

For: **Analytical Method Comprising Addition in Two or More Positions and a Device or Test Kit Therefor**

PRELIMINARY AMENDMENT

BOX PCT
Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Prior to calculation of the filing fee and first action by the Examiner, please amend the present application as follows:

In the Claims:

Please amend claims 1-33 as follows:

Claim 1, line 20, replace "characterized in that" with --wherein--.

Claim 2, lines 1-2, replace "characterized in that" with --wherein--.

Claim 3, lines 1-2, replace "characterized in that" with --wherein--.

4. The method according to claim 1, wherein [any of the claims 1-3, characterized in that] Reactant* is pre-deposited in its application zone ($LZ_n \cdot R^*$).

5. (Amended) The method according to claim 1, wherein [any of the claims 1-4, characterized in that] liquid_{n+1} is added to LZ_{n+1} before or substantially simultaneously with adding liquid_n to LZ_n , with the exception of $n=m$, which zone lacks the zone LZ_{n+1} .

6. (Amended) The method according to claim 1, wherein [any of the claims 1-5, characterized in that] LZ_{n+1} finishes where LZ_n starts, with the exception of $n=m$, which zone lacks the zone LZ_{n+1} .

7. (Amended) The method according to claim 1, wherein [any of the claims 1-6, characterized in that] application of liquid is performed substantially simultaneously in all $LZ_m \cdot LZ_n \cdot LZ_1$.

8. (Amended) The method according to claim 1, wherein [any of the claims 1-7, characterized in that] $m \leq 6$; n' is 1, 2 or 3, $n'' > n'$; $LZ_{n'+1}$, $LZ_{n'+2}$, $LZ_{n'+3}$, $LZ_{n'-1}$, and $LZ_{n'-2}$ are application zones for liquids intended for transport of Reactant* or other reactant or buffer without reactant, as far as allowed by m , n'' and n' .

9. (Amended) The method according to claim 1, wherein [any of the claims 1-8, characterized in that] at least one of the zones $LZ_m \cdot LZ_n \cdot LZ_1$ comprises a pad or material layer applied on the flow matrix.

10. (Amended) The method according to claim 1, wherein [any of the claims 1-8, characterized in that] the zones $LZ_m \dots LZ_n \dots LZ_1$ have zone spacers between each other.

11. (Amended) The method according to claim 1, wherein [any of the claims 1-10, characterized in that] the composition of transported components from an application zone LZ_n is not the same as from the nearest adjacent application zone LZ , in which flow is initiated, (LZ_{n+1} and LZ_{n-1} , with the exception of $n=m$ and $n=1$, which zones lack LZ_{n+1} and LZ_{n-1} , respectively).

12. (Amended) The method according to claim 1, wherein [any of the claims 1-11, characterized in that] at least one reactant, other than Reactant*, is pre-deposited in an application zone $LZ_n \dots R$ for liquid intended for transport of the reactant.

13. (Amended) The method according to claim 1, wherein [any of the claims 1-12, characterized in that] $m \leq 6$ and [that] n' for the application zone for sample ($LZ_n S$) is 1, 2 or 3.

14. (Amended) The method according to claim 1, wherein [any of the claims 1-13, characterized in that] Reactant* has biospecific affinity for the analyte so that Reactant* is incorporated into a complex Reactant'---Analyte---Reactant* in the detection zone in an amount related to the amount of analyte in the sample, in which complex Reactant' has biospecific affinity to the analyte and is

(a) Reactant I, or

(b) a reactant to which Reactant I exhibits biospecific affinity and which is transported from LZ_nS or from an application zone downstream of LZ_nS .

15. (Amended) The method according to claim 1, wherein [any of the claims 1-14, characterized in that] the matrix comprises at least one calibrator zone (CZ), in which calibrator is bound to, or in advance has been bound to the matrix.

Claim 16, lines 1-2, replace “characterized in that” with --wherein--.

17. (Amended) The method according to claim 1, wherein [any of the claims 1-16, characterized in that]

- a. the analyte is chosen among antigens generally, and
- b. the method is performed as part of diagnosing allergy or autoimmune disease.

Claim 18, line 18, replace “characterized in that” with --wherein--.

19. (Amended) The device according to claim 18, wherein [characterized in that] $n'' > n'$ and [that] the device is intended for sequential transport of analyte and Reactant*.

20. (Amended) The device according to claim 18, wherein [characterized in that] $n'' = n'$ and [that] the device is intended for simultaneous transport of analyte and Reactant*.

21. (Amended) The device according to claim 18, wherein [any of the claims 18-20, characterized in that] Reactant* is pre-deposited in its application zone (LZ_nR^*).

22. (Amended) The device according to claim 18, wherein [any of the claims 18-21, characterized in that] LZ_{n+1} finishes where LZ_n starts, with the exception of $n=m$, which zone lacks the zone LZ_{n+1} .

23. (Amended) The device according to claim 18, wherein [any of the claims 18-22, characterized in that] $m \leq 6$; n' is 1, 2 or 3; $n'' > n'$; $LZ_{n'+1}$, $LZ_{n'+2}$, $LZ_{n'+3}$, $LZ_{n'-1}$, and $LZ_{n'-2}$ are application zones for liquids intended for transport of Reactant* or other reactant or buffer without reactant, as far as allowed by m , n'' and n' .

24. (Amended) The device according to claim 18, wherein [any of the claims 18-23, characterized in that] the zones LZ_m , LZ_n , LZ_1 have zone spacers between each other.

25. (Amended) The device according to claim 18, wherein [any of the claims 18-23, characterized in that] at least one of the zones LZ_m , LZ_n , LZ_1 comprises a pad or material layer applied on the flow matrix.

26. (Amended) The device according to claim 18, wherein [any of the claims 18-25, characterized in that] at least one reactant, other than Reactant*, is pre-deposited in an application zone LZ_n-R for liquid intended for transport of the reactant.

27. (Amended) The device according to claim 18, wherein [any of the claims 18-26, characterized in that] $m \leq 6$ and [that] n' for the application zone for sample (LZ_nS) is 1, 2 or 3.

28. (Amended) The device according to claim 18, wherein [any of the claims 18-27, characterized in that] the detection zone DZ comprises firmly anchored Reactant I, and [that] a reactant to which Reactant I exhibits biospecific affinity optionally is pre-deposited in LZ_nS or in an application zone downstream of LZ_nS .

29. (Amended) The device according to claim 18, wherein [any of the claims 18-28, characterized in that] the flow matrix comprises at least one calibrator zone CZ, in which a calibrator or a binder for the calibrator is firmly anchored in the matrix.

30. (Amended) The device according to claim 29, wherein [characterized in that] the calibrator zone or zones (CZ) have a binder for the calibrator firmly anchored in the matrix, and [that] calibrator optionally is pre-deposited in the matrix upstream of the calibrator zone or zones.

31. (Amended) The device according to claim 18, wherein [any of the claims 18-30, characterized in that] the device is intended for diagnosing allergy or autoimmune disease.


32. (Amended) A test kit, [characterized in that the kit comprises] comprising (i) a device according to claim 18, [any of claims 18-29] and (ii) Reactant*.

Claim 33, lines 1-2, replace "characterized in that" with --wherein--.

REMARKS

By the present Amendment, the claims are amended to omit their multiple dependency and for several matters of form in accordance with customary U.S. patent practice. Since these changes do not involve any introduction of new matter, entry is believed to be in order and is respectfully requested.

Respectfully submitted,



Holly D. Kozlowski
Reg. No. 30,468
Dinsmore & Shohl LLP
1900 Chemed Center
255 East Fifth Street
Cincinnati, Ohio 45202
(513) 977-8568

577905.01

ANALYTICAL METHOD COMPRISING ADDITION IN TWO OR MORE
POSITIONS AND A DEVICE AND TEST KIT THEREFOR

Technical field

- 5 The invention relates to a method for determination of an
analyte in a sample by use of biospecific affinity
reactants (Reactant 1, Reactant 2 etc.), one of which is
analytically detectable (Reactant*) and one is firmly
anchored in a detection zone in a transport flow matrix
10 (Reactant I). The sample (analyte) is transported by a flow
in the matrix from one application zone for liquid (LZS)
containing the analyte (sample) and/or a buffer, to the
detection zone (DZ), in which Reactant I is firmly
anchored. At the same time as the sample is transported in
15 the matrix the soluble reactants, including Reactant*, are
also being transported. In the detection zone Reactant* is
captured in an amount which is related to the amount of
analyte present in the sample. To achieve this, Reactant*
is chosen so that it may bind biospecifically directly to
20 Reactant I or indirectly via one or more added biospecific
affinity reactants (including the analyte). The amount of
analyte is then determined from the amount of Reactant*
bound in the detection zone. The transport flow may contain
zones, in which different biospecific affinity reactants
25 (e.g. Reactant*, but not analyte) have been applied in
advance (predeposited) in order to be dissolved and
transported along with the flow towards the detection zone.

- By reactants (including the analyte), exhibiting
30 biospecific affinity (bioaffinity reactants), are meant
individual members in the reactant pairs: antigen/hapten -
antibody; biotin - avidin/streptavidin; two complementary
single chains of nucleic acid etc. As antibodies antigen
binding antibody fragments such as Fab, F(ab)₂, single
35 chain Fv antibodies (scFv) etc. are considered. Relevant
reactants do not have to be naturally occurring but can
also be synthetically produced molecules/binders.

The type of test methodology in question has previously been used primarily for biospecific affinity reactants where at least one part of an employed reactant pair has exhibited protein structure, in particular in connection with so called immunochemical determination processes.

The biospecific affinity reactions are primarily performed in aqueous media (e.g. water).

The technique in question is well known and has often been applied to so called test strips, where the strip has functioned as a flow matrix. The flow has been initiated in the zone to which the sample has been added (LZS). The flow has often been lateral, i.e. parallel to the surface of the matrix, or of other types, e.g. in depth in the matrix.

The test protocols have been of so called inhibition type (competitive) or non-inhibition type (non-competitive, sandwich). See e.g. Behringwerke US 4,861,711; Unilever WO 88/08534; Abbot US 5,120,643; Becton Dickinson EP 234,232 and US 4,855,240; Abbot/Syntex US 4,740,468; Pharmacia AB, WO 96/22532, etc.

In this context one often mentions simultaneous and sequential methods (protocols) regarding certain reactants (especially analyte and Reactant*). In simultaneous variants analyte (sample) and the relevant reactant, e.g. Reactant*, are transported simultaneously into the detection zone. Simultaneous variants may be obtained, if a sample is pre-incubated/mixed with Reactant* or if Reactant* has been predeposited in the sample application zone or in a zone downstream of the sample application zone but before the detection zone. In sequential variants the analyte (sample) is transported before a reactant, e.g. Reactant*, into the detection zone. Sequential variants may be obtained, if the relevant reactant, e.g. Reactant*, is added to the same application zone as the sample after the

sample (analyte) has been transported out of the zone. A variant of sequential methodology is discussed in US 4,855,240 (Becton & Dickinson). As an alternative to the sample (analyte) being transported before "tracer"

5 (=Reactant*) in the same transport flow, US 4,855,240 describes separated transport flows, in which the time of transport is regulated such that sample (analyte) reaches the detection zone before the "tracer" (Reactant*).

- 10 The term simultaneous tests has often included every variant, in which sample and Reactant* are pre-incubated/mixed before being added to a flow matrix or in which sample is added to a flow matrix, in which Reactant* is predeposited in the sample application zone or
- 15 downstream thereof. The term sequential tests has similarly included every variant, in which Reactant* is added to the sample application zone after the sample has migrated out of its application zone. Thus, considerations have not been taken, concerning if the order of analyte and Reactant* is
- 20 changed during transport to the detection zone. If not otherwise stated, this nomenclature is also used for the present invention, but is now adapted so that there are several application zones for liquid. This view means that primarily the initial order is considered, when both
- 25 analyte and Reactant* are in soluble form, and not the order in which analyte and Reactant* are transported into the detection zone.

Disadvantages with prior art and objects of the invention.

- 30 The prior art has often involved practical problems on automation, primarily because pre-incubation or sequential addition of sample and reactants have often been required, often in a certain predetermined order defined by the test protocol used. The object of the invention is to (a)
- 35 facilitate automation, (b) avoid sequential addition of sample and the analytically detectable reactant (Reactant*), and (c) allow for pre-deposited Reactant* when using sequential methodology, which relates to analyte and

Reactant*. More general aims are to achieve high quality test results, preferably with improved sensitivity and precision than given by previous variants.

5 The invention

Surprisingly we have now discovered that if flow is initiated by almost simultaneous addition of liquid to two adjacent zones in a flow matrix, the liquid added in the downstream zone migrates before the liquid which has been
 10 added in the upstream zone in direction towards the detection zone. Our discovery involves that zonewise migration of liquids may also be obtained if addition of liquid in an upstream zone is performed after addition of liquid in the nearest downstream zone. By applying this
 15 discovery on the relevant type of analysis methods, improvements can be obtained regarding the objects stated above.

A first main aspect of the invention relates to the
 20 initially mentioned analysis methods and is characterized in that

A. the flow matrix exhibits at least two application zones for liquid arranged substantially adjacent to each other:

25

$LZ_m \quad . \quad . \quad . \quad LZ_n \quad . \quad . \quad . \quad LZ_1 \quad \quad \quad DZ$
 ----->

wherein

- 30 a) LZ_n is an application zone for liquid, where n is the position of the application zone LZ_n (n is an integer $2 < n \leq m$)
- b) m is the total number of application zones, in which flow is initiated,
- 35 c) one LZ_n is an application zone for sample (LZ_n, S) and one LZ_n is application zone for Reactant* (LZ_n, R^*) with $n' \geq n$,

- d) -----> is the direction of the flow, and
 e) DZ is detection zone, and

B. flow is initiated by adding liquid to each zone

- 5 $LZ_n . . LZ_n . . LZ_1$ in such a way that liquid_{n+1}, added to the application zone LZ_{n+1} , is transported through the matrix after liquid_n, added to the nearest downstream application zone LZ_n .
- 10 Liquid_{n+1} may easily migrate immediately after liquid_n, if the corresponding zones for application of liquid are adjacent to each other or if added liquid volumes are adapted for this aim.
- 15 In the most common case the above mentioned involves adding liquid_{n+1} to LZ_{n+1} before or primarily simultaneously with adding liquid_n to LZ_n . For $n = m$, LZ_{n+1} is lacking, and for that zone it is therefore not possible to add any liquid to LZ_{n+1} . Practical advantages are achieved if the addition is
- 20 performed primarily simultaneously for all $LZ_m . . LZ_n . . LZ_1$.

The number (m) of application zones for liquid

($LZ_m . . LZ_n . . LZ_1$) may in principle be any number with

- 25 the exception of one ($m \neq 1$). For practical reasons it is likely that in the future $2 \leq m \leq 10$, preferably $2 \leq m \leq 6$, such as $m = 2$ or 3 or 4 or 5.

The liquids added (liquid₁ . . . liquid_m) may consist of

- 30 only buffer solution or buffer solution plus a reactant (Reactant 1, Reactant 2 etc.), needed to make it possible for Reactant* to be captured in the detection zone in an amount related to the amount of analyte in the sample. Also Reactant* may be included in a liquid_n. As a rule the
- 35 composition of transported components from an application zone is not the same as from the nearest adjacent application zone, in which flow is initiated (LZ_{n+1} and LZ_n).

with the exception of $n = m$ and $n = 1$ for which the zones LZ_{n+1} and LZ_{n-1} , respectively, are lacking).

5 By the expression "substantially adjacent to each other" is meant that the application zones for liquid are immediately adjacent to each other or with an intermediate area of matrix which preferably is no more than about 2 mm, and particularly no more than about 1 mm.

10 A liquid added in an application zone may have a tendency to spread on top of the matrix to parts of the matrix being outside the zone. For adjacent zones this means that liquids may be mixed with each other in an undesired way. To avoid this, physical barriers delimiting two adjacent
15 application zones (zone spacers) are placed. The barriers should primarily be placed on top of the matrix, but may be extended down into the matrix without completely quenching the flow. Delimitation is primarily against an adjacent zone for application of liquid, but can of course extend
20 around a whole application zone for liquid. Liquid may also be introduced via pads or material layers applied on the matrix and from the same or a different material than the matrix material. In such a case there is no need for zone spacers.

25

Relevant reactants may be predeposited in an application zone for liquid (LZ_n) or between two such zones. An application zone for liquid, only intended for transporting buffering components and/or other components not

30 participating in the biospecific affinity reactions (i.e. liquid neither containing nor intended for transport of any reactant or analyte), is called LZ_nB below. An application zone for liquid (LZ_n), where the liquid contains a reactant or is intended for transport of a reactant, e.g. Reactant*,
35 Reactant 1, Reactant 2 etc., is called $LZ_n..R^*$, $LZ_n..R1$, $LZ_n..R2$ etc. below. If a liquid_n is to transport a combination of components, e.g. Reactant* and analyte (sample) the application zone will be common for the

components and will be designated $LZ_n \dots R2/R1$ etc. For the combination sample and Reactant*, the application zone will be $LZ_n R^*/S$ ($n' = n''$). That liquid_n is intended for transport of a certain reactant includes that the reactant in question also can be predeposited in the zone LZ_n . The latter includes that the reactant may be predeposited in an area downstream of the application zone for the relevant liquid but upstream of the nearest downstream located LZ (LZ_{n-1}), or if $n = 1$ only upstream of the detection zone (as LZ_{n-1} then is lacking).

By predeposition is meant that a reactant is added in advance to the matrix and in a way so as not to spread in the matrix until it is reached by liquid, which has been applied to initiate flow. Predeposition of reactants may be performed in a way known per se. (See e.g. Behringwerke US 4,861,711; Unilever WO 88/08534; Abbot US 5,120,643; Becton Dickinson EP 284,232). It is important that arrangements are made so that the reactant in question is quickly dissolved, when liquid passes through an area, containing predeposited reactant. In order to achieve quick dissolution it has been common to incorporate reactants in substances that as such dissolve quickly. This type of substances are often hydrophilic with polar and/or charged groups, such as hydroxy, carboxy, amino, sulphonate etc. In particular there may be mentioned hydrophilic quickly soluble polymers, e.g. having carbohydrate structure, simple sugars including mono-, di- and oligosaccharides and corresponding sugar alcohols (mannitol, sorbitol etc.). It is common practice to first coat the application zone in question with a layer of the quickly soluble substance, and then the reactant is applied, optionally followed by one additional layer of quickly soluble substance. An alternative way is by incorporating the reactant in particles of quickly soluble material which then are deposited in the relevant zone of the matrix.

Some of the most important embodiments regarding the application zones for liquid may be summarized: $2 \leq m \leq 6$; n' is 1, 2 or 3; $n'' > n'$ or $n'' = n'$; $LZ_n.S$ is the application zone for sample and optionally also for

5 Reactant* or other reactant; $LZ_{n'-1}$, $LZ_{n'+2}$, $LZ_{n'+3}$, $LZ_{n'-1}$, and $LZ_{n'-2}$ are application zones for liquids intended for transport of Reactant* or other reactant or buffer without reactant as far as allowed by m , n'' and n' .

- 10 Transport flow through the particular types of matrix may be achieved by the action of capillary forces, e.g. by starting with a substantially dry matrix. A sucking body may be placed at the end of the flow as an aid. Flow, meaning transport of primarily only dissolved components,
- 15 may be achieved if an electrical field is applied across the matrix.

Test protocols

By use of the invention reactants and analyte can be made

- 20 to migrate zonewise as individual components or together in different combinations towards the detection zone. The exact sequence of application zones is determined by the test protocol to be utilized.
- 25 The invention may be applied to competitive (inhibition) as well as non-competitive (non-inhibition) test variants irrespective of if these are simultaneous or sequential regarding any reactant. Illustrative systems are shown schematically below in form of the complexes formed. "-"
- 30 relates to firm anchoring to the matrix, "---" relates to binding via biospecific affinity. For the sake of simplicity it has been assumed that reactants used are monovalent regarding utilized binding sites.

A. Sandwich protocol (non-inhibition)

Reactant I and Reactant* both have biospecific affinity for the analyte. x = number of moles of Reactant I on the matrix and y = number of moles of analyte (= number of moles of Reactant*), bound to Reactant I.

Complex in the detection zone:

Matrix $(\text{-Reactant I})_{x-y} (\text{-Reactant I --- analyte --- Reactant*})_y$

10

Simultaneous variants:

$m = 2$: $\text{LZ}_2\text{R}^*/\text{S}$ LZ_1B DZ

Sequential variants:

15 $m = 2$: LZ_2R^* LZ_1S DZ .

$m = 3$: LZ_1R^* LZ_2B LZ_1S DZ and alternatives where the buffer zone has position 1 or 3.

$m = 4$: LZ_1B LZ_1R^* LZ_2B LZ_1S DZ and alternatives where any of the buffer zones is placed in position 1.

20 $m = 5$: The same sequence as for $m = 4$ with the exception that an extra buffer zone is placed in position 1.

B. Sandwich protocol (non-inhibition):

Reactant I exhibits biospecific affinity for Reactant II.

25 Both Reactant II and Reactant* have biospecific affinity for the analyte. x = number of moles of Reactant I on the matrix, y = number of moles of analyte (= number of moles of Reactant*), bound to Reactant I via Reactant II. $y + z$ is the number of moles of Reactant II bound to Reactant I.

30

Complex in the detection zone:

Matrix $(\text{-Reactant I})_{x-z-y} (\text{-Reactant I --- Reactant II})_z (\text{-Reactant I --- Reactant II --- analyte --- Reactant*})_y$

35 Simultaneous variants:

$m = 2$: The same as for protocol A with the exception that $\text{LZ}_2\text{R}^*/\text{S}$ is $\text{LZ}_2\text{R}^*/\text{S}/\text{RII}$ or that LZ_1B is LZ_1RII .

$m = 3$: $\text{LZ}_1\text{R}^*/\text{S}$ LZ_2B LZ_1RII DZ or

LZ₃R*/S LZ₂RII LZ₁B DZ.

Sequential variants:

m = 2: The same as for protocol A with the exception that

- 5 LZ₁S is replaced by LZ₁S/RII.

m = 3: LZ₃R* LZ₂B LZ₁S/RII DZ or

LZ₃R* LZ₂S LZ₁RII DZ or

LZ₃R* LZ₂S/RII LZ₁B DZ.

m = 4, 5, 6: In analogy with protocol A sequences with up

- 10 to 6 application zones for liquid may be considered.

C. Inhibition protocol:

Reactant I is an analyte analogue, firmly anchored to the matrix, Reactant III exhibits biospecific affinity for the

15 analyte and Reactant* has biospecific affinity for Reactant III. x = number of moles of Reactant I on the matrix. y = number of moles of Reactant III (= number of moles of Reactant*), bound to the matrix via Reactant I. The conditions are selected so that y is a measure of the

20 amount of analyte in the sample.

Complex in the detection zone:

Matrix (-Reactant I)_{x-y} (-Reactant I --- Reactant III --- Reactant*)_y

25

Simultaneous variants:

m = 2: LZ₂R*/RIII/S LZ₁B DZ.

Sequential variants:

- 30 m = 2: LZ₂R* LZ₁/RIII/S DZ.

m = 3, 4 and 5: May be built up in analogy with protocol A.

D. Inhibition protocol

- Reactant I exhibits biospecific affinity for both Analyte
- 35 and Reactant*. Reactant* is a soluble analyte analogue. x + y is the number of moles of Reactant I on the matrix, x and y are the number of moles of Reactant* and Analyte, respectively, being bound to the matrix.

Complex in the detection zone:

Matrix $(-\text{Reactant I} \text{ --- Reactant*})_x (-\text{Reactant I} \text{ --- Analyte})_y$:

5

Simultaneous variant:

m = 2: $\text{LZ}_2\text{R}^*/\text{S}$ LZ_1B DZ

Sequential variant:

10 m = 2: LZ_2R^* LZ_1S DZ

m = 3, 4 and 5 may be built up in analogy with protocol A.

Matrices

- The matrix defines the space in which the flow is transported. The matrix may be the inner surface of a simple flow channel (e.g. a capillary), the inner surface of a porous matrix having a system of flow channels (porous matrix) etc. extending through. For the sake of simplicity, matrices, usable in this variant of the invention, will be called flow matrices. Porous matrices may exist in the form of monoliths, sheets, columns, membranes, single flow channels having capillary dimensions or aggregated systems of such flow channels etc. They may also exist in the form of particles packed in column casings, compressed fibres etc. The inner surface of the matrices, i.e. the surface of the flow channels, should be hydrophilic, such that aqueous media (usually water) may be absorbed and transported through the matrices. The smallest inner dimension of the flow channels should be sufficiently large for allowing transport through the matrix of the reactants being used. The rule of thumb is that suitable matrices are selected among those having flow channels with the smallest inner dimension (often as a diameter for round channels) in the interval 0.4-1000 μm , preferably 0.4-100 μm if the matrix exhibits a system of mutually communicating flow channels. Flow channels having a smallest inner dimension in the upper part of the interval 0.4-1000 μm are primarily of

interest for simple unbranched channels, through which flow is driven by an externally imposed pressure or suction.

- Relevant matrices are often built up from a polymer, e.g. nitrocellulose, nylon etc. The material in the matrix as well as the physical and geometrical design of the flow channels may vary along the flow depending on what a certain part of the matrix is to be used for (Pharmacia AB WO 96/22532; Medix WO 94/15215).

10

Detection zone

- In the detection zone, Reactant I is firmly anchored to the matrix with bonds not allowing unintentional transport of Reactant I under the test conditions. Attachment of
- 15 Reactant I to the matrix may be covalent, via physical adsorption, via biospecific affinity etc. Like prior art in this field the invention may utilize combinations of binding types, e.g. covalent binding to the matrix of a biospecific affinity reactant directed to Reactant I. In
- 20 particular may be mentioned a matrix exhibiting a physically adsorptively or covalently bound member of a specific binding pair (reactant pair) in combination with Reactant I coupled or conjugated to the other member of the specific binding pair, or a matrix exhibiting a similarly
- 25 bound antibody directed to Reactant I. As examples of specific binding pairs may be mentioned immunological binding pairs, such as antigen-antibody and hapten-antibody, biotin-avidin or -streptavidin, lectin-sugar, hormone-hormone receptor, nucleic acid duplex. If reactant
- 30 I binds to the matrix via another reactant according to the above, Reactant I need not be immobilized in the matrix but may either be movably (diffusively) predeposited in the matrix in an area or zone that is separated from the detection zone, or it may be added together with or
- 35 separately from the sample. Anchoring of Reactant I to the matrix may be achieved via particles having been deposited in/on the matrix and to which Reactant I is covalently, physically adsorptively or biospecifically etc. bound. The

particles attach to the matrix either because their size has been selected such that they cannot be transported through the matrix or via physical adsorption. See inter alia Abbott/Syntex US 4,740,468; Abbott EP 472,376;

- 5 Hybritech EP 437,287 and EP 200,381; Grace & Co. EP 420,053; Fuji Photo Film US 4,657,739; Boehringer Mannheim WO 94/06012. For the invention the latter variant with smaller particles adsorbing physically to the matrix has been shown to be good.

10

In one and the same transport flow there may be several detection zones (DZ1, DZ2 etc.). One or more of the detection zones may relate to the same or different analytes. If the analytes are different Reactant I is

- 15 usually different for each DZ.

Analytically detectable reactant (Reactant*)

In the invention Reactant* cannot be an analyte. Usually analytical detectability is obtained because a natural

20 reactant, e.g. an antibody or an antigen or a hapten, is provided with an analytically detectable group. Well known examples of often used groups are enzymatically active groups (enzyme, co-factor, co-enzyme, enzyme substrate etc.), fluorogenic, chromophoric, chemiluminiscent,

- 25 radioactive groups etc. Groups being detected by means of a biospecific affinity reactant usually also are referred to this category, e.g. biotin, hapten, class-, subclass- and species-specific determinants in immunoglobulins etc.

- 30 A preferred label group is particles optionally containing any of the detectable groups above, such as fluorophoric groups or chromogenic groups (coloured particles). Useful particles often have a size in the interval of 0.001-5 μm . The particles may have colloidal dimensions, so called sol
- 35 (i.e. usually spherical and monodisperse having a size in the interval 0.001-1 μm). Especially metal particles (e.g. gold sol), non-metal particles (e.g. SiO_2 , carbon, latex

and killed erythrocytes and bacteria) may be mentioned. Also particles of non-colloidal dimensions but with focus on non-sedimenting capability have been used. These have been more or less irregular and more or less polydisperse

5 (carbon particles < 1 μm ; Pharmacia AB, WO 96/22532).

For particles as label group reference is made to Unilever WO 88/08534; Abbott US 5,120,643; Becton Dickinson EP 284,232 among others.

10 In connection with the development that has led to the present invention it was surprisingly found that good results may be obtained if one simultaneously utilizes:

- 15 (a) Reactant* with label particles according to the above as a detectable group, and
- (b) a detection zone, in which Reactant I has been anchored to the matrix via particles substantially
- 20 having dimensions that would allow transport of the particles as such through the matrix.

We have achieved functioning systems, in which label particles and anchoring particles substantially have the

25 same dimensions. This means with great probability that the label particles may be larger than the anchoring particles and vice versa, as long as they remain smaller than the flow channels defined by the matrix. The system may function with or without pre-deposition of Reactant* in the

30 intended application zone. This embodiment is part of an invention, described in our co-pending PCT application: "Analytical method using particles and test kit for performing the method" (based on SE 9704935-7). This separate patent application is incorporated herein by

35 reference.

Analytes

The invention is primarily adapted for determination of biospecific affinity reactants of the types initially mentioned. The reactants may be a cell or a virus or a part thereof. In particular antigen, such as an immunoglobulin or an antibody may be mentioned. For immunoglobulins the determination may relate to a certain Ig and/or certain Ig subclass. For antibodies the determination may relate to a certain specificity, optionally also the Ig class or the Ig subclass of the antibody. Relevant Ig classes are IgA, IgD, IgE, IgG and IgM. Relevant Ig subclasses are IgG1, IgG2, IgG3 and IgG4.

In sandwich variants (according to protocols A and B, above) the analyte may be an antibody, directed to an allergen/antigen/hapten and be derived from a certain species, a certain Ig class or a certain Ig subclass. In this case Reactant* may be an analytically detectable antibody directed to an epitope specific for the species, Ig class or Ig subclass and with Reactant I (protocol A) or Reactant II (protocol B) as the allergen/antigen/hapten. Alternatively the reverse may be selected, i.e. Reactant* is the allergen/antigen/hapten and Reactant I and Reactant II, respectively, is the antibody, directed to the analyte. When the analyte is an antigen in general, both Reactant I and Reactant* may be antibodies, directed to the antigen, in protocol A. For protocol B it is Reactant II and Reactant* that are antibodies directed to the antigen.

Competitive variants are most interesting for low molecular analytes. Illustrative examples are antigen and hapten. For protocol C Reactant I may be the antigen or the hapten, firmly anchored to the matrix, Reactant III may be an antibody, directed to the antigen, and Reactant* may be an antibody, directed to Reactant III. For protocol D Reactant I may be an antibody directed to the analyte and Reactant* may be the analyte labelled with an analytically detectable group.

The method of the invention may be performed as part of diagnosing allergy or autoimmune disease.

- 5 For the inventors it has been of special interest to measure anti-allergen antibodies of IgE or IgG class, for the latter preferably with focus on any of the subclasses mentioned. Measuring of allergen-specific antibodies can be utilized when diagnosing IgE mediated allergy.

10

Samples

Relevant samples may be of biological origin, e.g. from different body fluids (whole blood, serum, plasma, urine, saliva, tear fluid, cerebrospinal fluid etc.), from cell
15 culture media, processing procedures in biotechnology, from tissue extracts, from food stuff, from the environment (environmental analysis samples) etc. The samples may be pretreated in order to fit e.g. the matrix, the test protocol involved etc.

20

Calibrators

Determination methods of the type that the invention is related to, involve that the detectable signal from the analytically detectable reactant (Reactant*) is measured
25 and the measured signal (sample value) is taken as a measure of the amount of analyte present in the sample. To transfer the measurement signal to actual amounts of analyte the signal is usually compared to the corresponding signal (calibrator value) of known standard amounts of
30 analyte (calibrators). In connection with the present invention a new calibrator system has been developed, which applied to the present invention constitutes a best embodiment.

- 35 This separate invention means that the used calibrator in advance has been anchored to a matrix (matrix calibrator), preferably of the same type as the one utilized for sample run. When measuring calibrator values, matrix calibrator is

- allowed to bind to Reactant*, and then the measurement signal from Reactant* is measured in a way known per se. By utilizing different amounts of matrix calibrator a series of calibrator values may be obtained corresponding to
- 5 different pre-determined amounts of analyte in sample (standard amounts, dose-response curve, calibration curve).

- Alternatively, instead a binder for the calibrator has been anchored to the matrix, and calibrator is added at the
- 10 determination of calibrator value, optionally pre-deposited in the matrix upstream of the calibrator zone(s) to be dissolved by sample solution or buffer at the determination. When a calibrator binder is bound to the matrix, the calibrator may either be movably (diffusively)
- 15 pre-deposited in the matrix in a zone separated from the detection zone, or be added together with or separately from the sample. The calibrator binder is usually one member of a specific binding pair (reactant pair), the other member of the binding pair being coupled or
- 20 conjugated to the calibrator substance. As examples of such specific binding pairs may be mentioned immunological binding pairs such as antigen-antibody and hapten-antibody, biotin-avidin or -streptavidin, lectin-sugar, hormone-hormone receptor, nucleic acid duplex.

- 25 Applied to the present invention our new calibrator system involves primarily that the transport flow passes one or more zones with a calibrator, firmly anchored to the matrix in the respective calibrator zone (CZ).

- 30 Anchoring of a calibrator to the matrix in a calibrator zone may be performed according to the same principles as for anchoring of Reactant I to a detection zone.

- 35 Calibrator zones should be located downstream of an application zone for liquid, intended for transport of Reactant*. In relation to the detection zone (DZ) the calibrator zone is preferably located upstream.

Our invention relating to calibrators is described in detail in our co-pending PCT application with the title "Method using a new calibrator and a device and test kit including the calibrator" (based on SE 9704933-2). This application is incorporated herein by reference.

A second main aspect of the invention

The flow matrix according to the above containing two or more application zones for liquid, optionally in the form of a kit wherein the flow matrix is comprised together with the analytically indicatable reactant, constitutes a second main aspect of the invention.

The invention is illustrated in the following non-limiting experimental part.

EXAMPLE 1: SEQUENTIAL METHOD WITH THE ZONE SEQUENCE: LZ₁B, LZ₁R*, LZ₂B, LZ₁S, DZ. DETECTION OF hIge IN TEST VARIANT WITH CARBON PARTICLE CONJUGATE

Methods and materials

Adsorption of phenyldextran to polystyrene particles:

Phenyldextran (substitution degree: 1 phenyl group on each fifth monosaccharide unit = 20%, Mw dextran 40,000, Pharmacia Biotech AB, Uppsala, Sweden) was adsorbed to polystyrene particles (0.49 µm Bangs Laboratories, USA) by incubations under stirring with phenyldextran dissolved in deionized water to 1) 5 mg/ml, 10% particle suspension, RT 30-60 minutes; 2) 5 mg/ml, 5% particle suspension, RT 1 h; 3) 20 mg/ml, 1-2% particle suspension, RT 3 h or overnight. The particles were subsequently washed twice with deionized water. The particle suspensions were centrifuged between each incubation and wash (12,100xg, 25 min, Beckman, J-21, JA-20, 10,000 rpm). The particle suspension was finally sonicated (Ultrasonic bath, Branson 5210, 5 min).

Coupling of anti-human IgE antibody (anti-hIgE) to polystyrene particle:

Anti-hIgE was coupled to phenyldextran coated polystyrene particles with CDAP (1-cyano-4-dimethylamino-pyridinium bromide (Kohn J and

5 Wilchek M, FEBS Letters 154(1) (1983) 209-210).

Desalting and change of buffer of anti-hIgE was performed by gel filtration (PD-10, Pharmacia Biotech AB) in NaHCO_3 , 0.1 M, pH 8.5. 2.3 g of polystyrene particles (coated with phenyldextran according to above) in 2% solution in 30% (by volume) acetone were activated with 17 ml CDAP (0.44 M) and 14 ml TEA (0.2 M triethylamine, Riedel-deHaën, Germany). CDAP was added with stirring for 150 seconds and TEA for 150 seconds. The particles were washed with 30% (by volume) acetone and centrifuged at 12,100xg (25 min, Beckman, J-21, JA-20, 10,000 rpm). 17 of anti-hIgE was coupled to the activated particles (2%, 0.15 g in 0.1 M NaHCO_3 , pH 8.5) in incubating with stirring overnight at +4°C. The particles were centrifuged and decanted before deactivating with glutamic acid 0.05 M and aspartic acid 0.05 M in 0.1 M NaHCO_3 , pH 8.5 when incubating with stirring overnight at +4°C. Coupled particles were washed once with 0.1 M NaHCO_3 , 0.3 M NaCl, pH 8.5, once with 0.1 M HAC, 0.3 M NaCl pH 5, once with 0.1 M NaHCO_3 , pH 8.5 and once with 20 mM borate buffer pH 8.5.

The concentration of particles was determined spectrophotometrically at A_{600} nm with untreated particles as reference. Concentration of coupled protein was determined by having anti-hIgE present during the coupling and cpm measurement.

Carbon particle conjugate (Reactant*): This was prepared by anti-hIgE being adsorbed to carbon particles (sp100, < 1 μm , Degussa, Germany) according to WO 96/22532 (Pharmacia AB). The final solution used in the flow matrix contained 400 μg of carbon particles per ml.

Deposition of anti-hIgE-coupled particles on membrane: On nitrocellulose sheets (Whatman, 8 μ m, length 5 cm and width 25 cm with polyester backing, anti-hIgE particles (prepared according to the above) were deposited in a zone over the width of the sheet (future detection zone) with Linear Striper (IVEK Corporation). The flow was 1 μ l/sec and 1 μ l/cm. The particles were diluted in borate buffer (20 mM, pH 8.5, Dextran T5000 4.2% w/w, sorbitol 5.8% w/w). The amount of deposited anti-IgE antibody was about 1000 ng/cm. The sheets were dried for 1 h at 30°C.

Zones for application of buffer, sample and carbon particle conjugate: Well separated from the zone, containing deposited material, 4 Inplastor strips (Mylar with glue on one side, Gelman) with a width of 1 mm were placed in parallel with the zone and parallel with each other at a distance of 5 mm from each other (zone spacers). The Inplastor strips thus defined four zones with a width of 5 mm. The sheets were cut perpendicularly relative to the zone containing deposited material, to strips with a width of 0.5 cm (the length of the strip then became 5 cm) (Singulator: Matrix 1201 membrane cutter, Kinematic automation). The final strips exhibited four parallel zones (application zones) separated by Inplastor strips as zone spacers and a separate zone with deposited anti-hIgE antibody (detection zone). As a comparison strips without zone spacers, i.e. without separated application zones were produced.

Test methodology: Strips with separated application zones were mounted on a plane holder. At the top (0.5 cm) of the strip (and with the detection zone as the nearest zone) a sucking membrane was placed (Whatman, 17 Chr, width 3 cm). The holder also gave a constant pressure on the sucking membranes. For simultaneous application of reagents to the four subzones a 4 channel Multipipette (Labystems) was

used. The multipipette was loaded so that serum sample (30 μ l) was applied in the application zone nearest to the detection zone in the order of buffer (30 μ l), carbon particle conjugate (30 μ l) and buffer (30+30 μ l) in the
5 respective upstream application zone. For sequential application to the strips without zone spacers, 30 μ l of sample were first applied to the lower end of the strip. After suction of sample volume, buffer (30 μ l), carbon particle conjugate (30 μ l) and buffer (30+30 μ l) were added
10 successively after suction. The carbon particle conjugate was prepared according to above and suspended in buffer. The buffer was NaPO_4 0.1 M, BSA 3%, NaN_3 0.05%, sucrose 3%, sodium chloride 0.2%, phenyldextran 0.05%, bovine gammaglobulin 0.05%, pH 7.5. The binding of the carbon
15 particle conjugate to the detection zone was quantitated by measuring of absorbance (Ultrosan XL, Enhanced Laser Densitometer, LKB). IgE with standard concentrations in plasma environment (0; 0.5; 2; 10; 50, and 200 KU/ μ l) was used as samples.

Results

Having four application zones for liquid and simultaneous addition, the liquids were migrating in the order of the application zones, i.e. the sample being in the zone
25 nearest to the detection zone was migrating first, without being mixed with the washing solution of the following application zone, which solution in turn started migrating, when the sample had been transported out of the application zone for samples. Correspondingly the liquids of the
30 remaining zones were migrating sequentially without being mixed.

Table 1: Analysis results from runs with sequential addition in one zone and from simultaneous addition in four
35 subzones (buffer, analytically detectable reactant, buffer, sample).

| IgE KU/L | Sequential addition in one zone | Simultaneous addition in 4 subzones |
|----------|---------------------------------------|---|
| | (Abs x1000) | (Abs x1000) |
| 0,5 | 0 | 12 |
| 2 | 312 | 207 |
| 10 | 1241 | 831 |
| 50 | 1921 | 1560 |
| 200 | 2115 | 2044 |

In Table 1 is shown that the uptake decreases slightly for

5 strips with discrete application zones compared to when addition is performed in one and the same zone. The decrease is, however, marginal. Therefore the experiment shows that generally the same result may be achieved if simultaneous addition is performed to the zone sequence
 10 LZ₂B, LZ₂R*, LZ₂B, LZ₂S as if sample, Reactant* and buffer are added sequentially to a common application zone.

If a firmly anchored anti-IgE antibody (Reactant I) is replaced by an allergen a determination method for IgE

15 antibodies directed to the allergen is obtained. Analogously, test systems related to antibodies of another class/subclass and with another specificity may be determined. Application zones for only buffer may be omitted. For additional alternative test protocols and
 20 analytes see above under the headings "Test protocols" and "Analytes".

EXAMPLE 2: SEQUENTIAL METHOD WITH THE ZONE SEQUENCE: LZ₄B, LZ₃R*, LZ₂B, LZ₁S, DZ. DETECTION OF hIgE IN TEST VARIANT WITH FLUORESCENT DETECTION CONJUGATE

5 Methods and materials

Coupling of anti-human IgE antibody (anti-hIgE) to a

polystyrene particle: Anti-hIgE was coupled to polystyrene particles coated with phenyldextran (prepared according to Example 1) with CDAP (1-cyano-4-dimethylaminopyridinium

- 10 bromide) (Kohn J and Wilchek M, FEBS Letters 154(1) (1983) 209-210). Desalting and buffer change of anti-hIgE was performed by gel filtration (PD-10, Amersham Pharmacia Biotech AB) in NaHCO₃, 0.1 M, pH 8.5.

- 15 0.35 g of polystyrene particles (2% solution) were activated with 5.2 ml of CDAP (0.44 M) and 4.2 ml of TEA (0.2 M triethylamine, Riedel-deHaën, Germany). CDAP was added with stirring for 60 seconds and TEA for 120 seconds. A five times excess of ice-cooled deionized water was
- 20 added. The particles were centrifuged at 12,100xg (25 min., Beckman, J-21, JA-20, 10,1000 rpm). The resulting pellet was dissolved in ice-cooled, deionized water and washed once with ice-cooled deionized water and then centrifuged at 12,000 x g. 50 mg of anti-hIgE were coupled to the
- 25 activated particles (2%, 0.35 g in 0.1 M NaHCO₃, pH 8.5). Incubation with stirring was the performed for 1 hour at +4°C. After centrifugation, the particles were deactivated with glutamic acid, 0.05 M, and aspartic acid, 0.05 M in 0.1 M NaHCO₃, pH 8.5. Incubation and stirring was then
- 30 performed overnight at +4°C. Coupled particles were washed twice with 20 mM borate buffer, pH 8.5, whereupon the particle concentration was determined spectrophotometrically at A_{600nm} with untreated particles as reference. Coupled protein concentration was determined
- 35 by having radioactive anti-hIgE present during the coupling.

Coupling of anti-hIgE antibodies to detection particles:

Antibodies to hIgE cleaved with pepsin to fab'2 fragments were coupled to fluorescent polystyrene particles having aldehyde groups on their surface (Molecular Probes C-17177

- 5 TransFluoSphere, aldehyde-sulphate microspheres, 0.1 μm , 633/720, 2% solids). 23 mg of antibody were then coupled to 66 mg of particles in 50 mM NaPO_4 , pH 6.5, overnight at room temperature, whereupon 205 μL of NaCNBH_4 (5 M) were added to reduce the coupling for 3 hours at room
- 10 temperature. Centrifugation was performed at 20,800 x g for 50 minutes (50 minutes in Eppendorf 5417R, 14,000 rpm), and deactivation in glutamic acid, 0.05 M, and aspartic acid, 0.05 M, in deionized water, pH 6.5, was then performed overnight with stirring at room temperature. After
- 15 centrifugation again at 20,800 x g, blocking was performed with 0.2% BSA in 50 mM NaPO_4 , pH 7.4, with 0.05% NaN_3 and incubation was carried out overnight at +4°C.

- Centrifugation was then performed again at 20,800 x g and washing was performed twice with blocking buffer which was
- 20 then used also for storage. The particle concentration was determined in a fluorimeter (Perkin-Elmer LS50B) with a standard curve prepared with the original particle. Coupled protein concentration was determined by having radioactive hIgE present during the coupling.

- 25 Deposition of anti-hIgE-coupled particles on membrane and application zones: Was performed according to Example 1, except that the Inplastor strips were replaced by strips of adhesive tape (2 mils clear polyester Arcare with glue on
- 30 one side).

- Test methodology: Strips with spaced application zones were mounted to an inclined plane, about 16°, in a holder. At the top (0.5 cm) of the strip (and with the detection zone
- 35 as the nearest zone), two sucking membranes (Whatman, 17 Chr, width 3.4 cm) were placed on top of each other. The holder also exerted a constant pressure on the sucking

- membranes. For simultaneous application of reagents to the four subzones, a multichannel Finn pipette (Labsystems) was used. The multipipette was charged so that serum sample (30 μ L) was applied to the application zone nearest to the
- 5 detection zone in the order of buffer (15 μ L), fluorescent particle conjugate (30 μ L) and buffer (30 + 30 μ L) in the respective application zone located upstream. For sequential application to the strips without zone spacer, 30 μ L of sample were first applied to the lower end of the
- 10 strip. After sucking of the sample volume, buffer (15 μ L), detection particle conjugate (30 μ L) and buffer (30 + 30 μ L) were successively added after sucking. The particle conjugate was suspended in assay buffer consisting of NaPO_4 0.1 M, BSA 3 %, NaN_3 0.05 %, sucrose 10 %, NaCl, 0.15 M,
- 15 bovine gammaglobulin 0.05 %, pH 7.5. The measurement of time started with the application of the sample, and the time until the last buffer had been sucked into the membrane was noted. The binding of the fluorescent particle conjugate to the detection zone was quantified by scanning
- 20 with a red diode laser (635 ± 5 nm). As sample were used IgE standard concentrations in plasma environment (0, 0.5, 2, 10, 50 and 200 KU/L).

Results:

- 25 Precisely as in Example 1, the liquids migrated out of the application zone in the existing order. The time for a whole test with simultaneous application was about 20 minutes, and the time for a test with sequential
- 30 application was about 25 minutes.

Table 2: Analysis results from runs with sequential application in one zone and from simultaneous application in four subzones (buffer, analytically detectable reactant, buffer, sample).

| KU/L | Simultaneous addition to four subzones | Sequential addition to one zone |
|------|--|---------------------------------------|
| 0 | 0.048* | 0.038* |
| 0.5 | 0.053 | 0.047 |
| 2 | 0.085 | 0.074 |
| 10 | 0.286 | 0.256 |
| 50 | 1.334 | 1.291 |
| 200 | 2.507 | 2.487 |

* = scanning signal (Vmm)

Table 2 shows that the uptake is comparable for strips with discrete application zones in comparison with addition to a single zone. The experiment therefore shows that the same result may be obtained if addition is made simultaneously to the zone sequence LZ₄B, LZ₃R*, LZ₂B, LZ₁S as if sample, Reactant* and buffer are added sequentially to a common application zone.

EXAMPLE 3: SEQUENTIAL METHOD WITH THE ZONE SEQUENCE: LZ₅B, LZ₄R*, LZ₃B, LZ₂S, LZ₁B, DZ. DETECTION OF BIRCH-SPECIFIC hIgE IN TEST VARIANT WITH FLUORESCENT DETECTION CONJUGATE

Methods and materials

Extraction of birch pollen allergen t3, Betula verrucosa: 1 part (weight) of birch pollen (Allergon, Sweden) was extracted with 10 parts (volume) of 0.1 M phosphate buffer, pH 7.4. The extraction was continued for 2 hours on a shaker table at +4 °C. The extract was centrifuged at 4000 rpm for 1.75 hours. After filtration, the solution was applied to a PD-10 column (Pharmacia Biotech AB) and eluted in 0.1 M NaHCO₃, pH 8.5. The t3 eluate (designated: t3 extract 1/14) was taken to amino acid analysis for determination of the total protein content.

Coupling of birch pollen allergen to polystyrene particle:
t3 extract was coupled to phenyldextran coated polystyrene particles (prepared according to Example 1) with CDAP. The coupling was effected analogously with the coupling of
5 hIgE.

Polystyrene particles (2128 mg) coated with phenyldextran in 30 % (by volume) acetone, 2 % particle suspension, were activated with 954 mg of CDAP (100 mg/ml in 30 % acetone)
10 and 7.63 ml of 0.2 M triethylamine (TEA, Riedel-de Haen, Germany). CDAP was added with stirring and TEA was added dropwise for 90 seconds and with stirring for totally 120 seconds. The reaction was stopped by the addition of 30 % acetone (4 times the volume) and centrifugation at 12,400 g
15 for 35 minutes. The particles were washed once with deionized water.

640 ml of t3 extract 1/14 in 0.1 M NaHCO_3 , pH 8.5, were added to the activated particles, and coupling was
20 continued for 1 hour on a shaker table. After centrifugation, the particles were deactivated with 0.05 M aspartic acid and 0.05 M glutamic acid in 0.1 M NaHCO_3 , pH 8.5. Incubation then took place on a shaker table overnight at +4 °C. The particles were then washed twice with 50 mM
25 NaPO_4 , 0.05 % NaN_3 , pH 7.4. The particle concentration was determined spectrophotometrically at 600 nm with uncoated polystyrene particles as reference. t3-coupled polystyrene particles were taken to amino acid analysis for determination of the total protein content.

30 Deposition of t3-coupled polystyrene particles on a membrane: To nitrocellulose sheets with polyester backing (Whatman, 8 μm , 5 cm width) were applied zones of t3-coupled particles diluted to 4 % particle content in 50 mM
35 NaPO_4 , 10 % sucrose, 0.05 NaN_3 , pH 7.4. The deposits were dried for 1 hour at 30 °C.

Zones for application of buffer, sample and detection

particle conjugate: Five 1 mm wide strips of adhesive tape (2 mils clear polyester, Arcare with glue on one side) were placed well separated from the zone containing the

- 5 deposited material and in parallel with the zone at a distance of 5 mm from each other. The tape strips thereby defined five different 5 mm wide zones. The sheets were cut perpendicularly to the zone containing deposited material to strips having a width of 0.5 cm (the length of the strip
10 then became 5 cm) (Singulator: Matrix 1201 membrane cutter, Kinematic automation). The final strips exhibited five zones (application zones) separated by tape strips as zone spacers and a separate zone with deposited birch pollen (detection zone). Strips without zone spacers, i.e. without
15 separated application zones, were prepared as a comparison.

Test methodology: Strips with separated application zones were mounted, and reagents were applied as in Example 2.

- Buffer (20 μ L) was applied to the zone closest to the
20 application zone, and then serum sample (30 μ L), buffer (20 μ L), detection particle conjugate (20 μ L) and buffer (30 + 30 μ L) in the respective application zone located upstream. For sequential application to the strips without zone spacer 20 μ L of buffer were first applied to the lower end
25 of the strip, and after sucking in thereof, 30 μ L of sample were applied in the same position and then buffer (20 μ L), fluorescent particle conjugate (20 μ L) and buffer (30 + 30 μ L). Before all applications, the preceding application had been sucked in by the strip. The detection particle
30 conjugate and the buffer were according to Example 2.

Results:

- With the application zone consisting of five subzones and with simultaneous addition thereto, it turned out that the
35 liquids, precisely as in the Examples above, migrated out of the application zone in the existing order. The time

required for a whole test with simultaneous addition was about 21 minutes, and the time needed for a whole test with sequential addition was about 27 minutes.

- 5 **Table 3:** Analysis results from runs with sequential addition in one zone and from simultaneous addition in 4 subzones (buffer, analytically detectable reactant, buffer, sample).

| | Simultaneous addition to 5 subzones | Sequential addition to 1 zone |
|-------|---|-------------------------------------|
| neg | 0.067* | 0.058* |
| pos 1 | 1.911 | 2.608 |
| pos 2 | 0.299 | 0.375 |

10

* = scanning signal (Vmm)

- Table 3 shows that the uptake is decreased to some extent for strips having discrete application zones compared with
15 addition to a single zone. The decrease is, however, marginal and is probably due to the fact that the flow rate in simultaneous application was somewhat delayed. The experiment therefore demonstrates that basically the same results may be achieved for simultaneous application to the
20 zone sequence LZ₅B, LZ₄R*, LZ₃B, LZ₂S, LZ₁B as if sample, Reactant* and buffer are applied sequentially to a common application zone.

25

CLAIMS

1. A method for determination of an analyte in a sample in a flow matrix by use of a transport flow of one or more biospecific affinity reactants, at least one of which is analytically detectable (Reactant*) and one is firmly anchored in the matrix (Reactant I), and the flow matrix comprises:
- 10 A) an application zone for liquid (LZ), containing buffer and sample and optionally one or more of the reactants, but not Reactant I,
- B) a detection zone (DZ) located downstream of LZ with the
- 15 firmly anchored reactant (Reactant I), and
- C) optionally one or more zones in which any of the reactants has been pre-deposited,
- 20 wherein (i) the flow towards the detection zone is initiated by addition of the liquid with sample in the application zone LZS for transport of analyte and reactants towards the detection zone (DZ), and (ii) the amount of Reactant* bound to DZ is detected, the detected amount
- 25 being related to the amount of analyte in the sample, **characterized** in that

I. the flow matrix comprises at least two application zones for liquid arranged substantially adjacent to each other:

30

LZ_m . . . LZ_n . . . LZ₁ DZ
 ----->

wherein

35

a) LZ_n is an application zone for liquid, and n is the position of the application zone LZ_n,

b) m is the total number of application zones in which flow is initiated ($m \geq 2$),

c) one LZ_n is an application zone for sample (LZ_n, S) and one LZ_n is for Reactant* (LZ_n, R^*) with $n' \geq n$,

d) -----> is the direction of the flow, and

e) DZ is the detection zone, and

10

II. flow is initiated by adding liquid to each zone LZ_m . . . LZ_n . . . LZ_1 in such a way that liquid_{n+1}, added to the application zone LZ_{n+1} , is transported through the matrix immediately after liquid_n, added to the nearest downstream application zone LZ_n .

15

2. The method according to claim 1, **characterized** in that $n' > n$ (sequential variants regarding analyte and Reactant*).

20

3. The method according to claim 1, **characterized** in that $n' = n$ (simultaneous variants regarding analyte and Reactant*).

25

4. The method according to any of the claims 1 - 3, **characterized** in that Reactant* is pre-deposited in its application zone (LZ_n, R^*).

30

5. The method according to any of the claims 1 - 4, **characterized** in that liquid_{n+1} is added to LZ_{n+1} before or substantially simultaneously with adding liquid_n to LZ_n , with the exception of $n = m$, which zone lacks the zone LZ_{n+1} .

6. The method according to any of the claims 1 - 5, **characterized** in that LZ_{n+1} finishes where LZ_n starts, with the exception of $n = m$, which zone lacks the zone LZ_{n+1} .
- 5 7. The method according to any of the claims 1 - 6, **characterized** in that application of liquid is performed substantially simultaneously in all LZ_m . . LZ_n . . LZ_1 .
8. The method according to any of the claims 1 - 7, **characterized** in that $m \leq 6$; n' is 1, 2 or 3; $n'' > n'$; $LZ_{n'+1}$, $LZ_{n'+2}$, $LZ_{n'+3}$, $LZ_{n'-1}$, and $LZ_{n'-2}$ are application zones for liquids intended for transport of Reactant* or other reactant or buffer without reactant, as far as allowed by m , n'' and n' .
- 10 9. The method according to any of the claims 1 - 8, **characterized** in that at least one of the zones LZ_m . . LZ_n . . LZ_1 comprises a pad or material layer applied on the flow matrix.
- 15 10. The method according to any of the claims 1 - 8, **characterized** in that the zones LZ_m . LZ_n . LZ_1 have zone spacers between each other.
- 20 11. The method according to any of the claims 1 - 10, **characterized** in that the composition of transported components from an application zone LZ_n is not the same as from the nearest adjacent application zone LZ , in which flow is initiated, (LZ_{n+1} and LZ_{n-1} , with the exception of $n = m$ and $n = 1$, which zones lack LZ_{n+1} and LZ_{n-1} , respectively).
- 25 12. The method according to any of the claims 1 - 11, **characterized** in that at least one reactant, other than Reactant*, is pre-deposited in an application zone $LZ_{n...R}$ for liquid intended for transport of the reactant.
- 35

13. The method according to any of the claims 1 - 12, **characterized** in that $m \leq 6$ and that n' for the application zone for sample $(LZ_n.S)$ is 1, 2 or 3.

14. The method according to any of the claims 1 - 13, **characterized** in that Reactant* has biospecific affinity for the analyte so that Reactant* is incorporated into a complex Reactant'---Analyte---Reactant* in the detection zone in an amount related to the amount of analyte in the sample, in which complex Reactant' has biospecific affinity to the analyte and is

(a) Reactant I, or

(b) a reactant to which Reactant I exhibits biospecific affinity and which is transported from $LZ_n.S$ or from an application zone downstream of $LZ_n.S$.

15. The method according to any of the claims 1 - 14, **characterized** in that the matrix comprises at least one calibrator zone (CZ), in which calibrator is bound to, or in advance has been bound to the matrix.

16. The method according to claim 15, **characterized** in that the calibrator zone or zones (CZ) have a binder for the calibrator firmly anchored in the matrix, the calibrator optionally being pre-deposited in the matrix upstream of the calibrator zone or zones.

17. The method according to any of the claims 1 - 16, **characterized** in that

- the analyte is chosen among antigens generally, and
- the method is performed as part of diagnosing allergy or autoimmune disease.

18. A device for determination of an analyte in a sample in a flow matrix by use of a transport flow of one or more biospecific affinity reactants, at least one of which is analytically detectable (Reactant*) and one is firmly
 5 anchored in the matrix (Reactant I), said device comprising a flow matrix having:

A) an application zone for liquid (LZ), containing buffer and sample and optionally one or more of the reactants, but
 10 not Reactant I,

B) a detection zone (DZ) located downstream of LZ with the firmly anchored reactant (Reactant I), and

15 C) optionally one or more zones in which any of the reactants has been pre-deposited,

characterized in that

20 the flow matrix comprises at least two application zones for liquid arranged substantially adjacent to each other:

LZ_m . . . LZ_n . . . LZ₁ DZ
 ----->

25

wherein

a) LZ_n is an application zone for liquid, and n is the position of the application zone LZ_n,

30

b) m is the total number of application zones in which flow is initiated ($m \geq 2$),

c) one LZ_n is an application zone for sample (LZ_n,S) and one LZ_n is for Reactant* (LZ_n,R*) with $n' \geq n$,

35

d) -----> is the direction of the flow, and

e) DZ is the detection zone.

19. The device according to claim 18, **characterized** in
5 that $n'' > n'$ and that the device is intended for
sequential transport of analyte and Reactant*.

20. The device according to claim 18, **characterized** in
that $n'' = n'$ and that the device is intended for
10 simultaneous transport of analyte and Reactant*.

21 The device according to any of the claims 18 - 20,
characterized in that Reactant* is pre-deposited in its
application zone ($LZ_{n''..R*}$).
15

22. The device according to any of the claims 18 - 21,
characterized in that LZ_{n+1} finishes where LZ_n starts, with
the exception of $n = m$, which zone lacks the zone LZ_{n+1} .

20 23. The device according to any of the claims 18 - 22,
characterized in that $m \leq 6$; n' is 1, 2 or 3; $n'' > n'$;
 $LZ_{n'+1}$, $LZ_{n'+2}$, $LZ_{n'+3}$, $LZ_{n'-1}$, and $LZ_{n'-2}$ are application zones
for liquids intended for transport of Reactant* or other
reactant or buffer without reactant, as far as allowed by
25 m , n'' and n' .

24. The device according to any of the claims 18 - 23,
characterized in that the zones LZ_m . LZ_n . LZ_1 have
zone spacers between each other.
30

25. The device according to any of the claims 18 - 23,
characterized in that at least one of the zones
 LZ_m . . LZ_n . . LZ_1 comprises a pad or material layer
applied on the flow matrix.
35

26. The device according to any of the claims 18 - 25, **characterized** in that at least one reactant, other than Reactant*, is pre-deposited in an application zone $LZ_n...R$ for liquid intended for transport of the reactant.

5

27. The device according to any of the claims 18 - 26, **characterized** in that $m \leq 6$ and that n' for the application zone for sample ($LZ_n.S$) is 1, 2 or 3.

10 28. The device according to any of the claims 18 - 27, **characterized** in that the detection zone DZ comprises firmly anchored Reactant I, and that a reactant to which Reactant I exhibits biospecific affinity optionally is pre-deposited in $LZ_n.S$ or in an application zone downstream of
15 $LZ_n.S$.

29. The device according to any of the claims 18 - 28, **characterized** in that the flow matrix comprises at least one calibrator zone CZ, in which a calibrator or a binder
20 for the calibrator is firmly anchored in the matrix.

30. The device according to claim 29, **characterized** in that the calibrator zone or zones (CZ) have a binder for the calibrator firmly anchored in the matrix, and that
25 calibrator optionally is pre-deposited in the matrix upstream of the calibrator zone or zones.

31. The device according to any of the claims 18 - 30, **characterized** in that the device is intended for diagnosing
30 allergy or autoimmune disease.

32. A test kit, **characterized** in that the kit comprises (i) a device according to any of claims 18 - 29 and (ii) Reactant*.

35

33. The test kit according to claim 32, **characterized** in that the kit additionally comprises (iii) a calibrator when a binder for the calibrator is firmly anchored in the matrix.

0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2

DECLARATION
and
POWER OF ATTORNEY

U.S. NATIONAL PHASE OF INTERNATIONAL APPLICATION



As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **Analytical Method Comprising Addition in Two or More Positions and a Device and Test Kit Therefor**, the specification of which was filed as International Application No. PCT/SE98/02463 on December 30, 1998,

☐ and was amended under Article 19 on _____
(if applicable)

☐ and was amended under Article 34 on _____
(if applicable)

☒ and was assigned U.S. Application Serial No. 09/582,734, and was amended on June 30, 2000.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits and/or U.S. Provisional application priority benefits under Title 35, United States Code, §119 of any foreign application(s) or U.S. Provisional applications for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

| Prior Foreign and U.S. Provisional Application(s) | | | | |
|---|---------|----------------------|------------------|----|
| | | | Priority Claimed | |
| Number | Country | Day/Month/Year Filed | Yes | No |
| 9704934-0 | Sweden | December 30, 1997 | X | |
| | | | | |

0552734-105500

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulation, §1.36(a) which occurred between the filing date of the prior application and the PCT international filing date of this application:

(Application Serial No.) (Filing Date)

(Status)
(patented, pending,
abandoned)

I hereby appoint Holly D. Kozlowski, Registration No. 30,468; Ronald J. Snyder, Registration No. 31,062; James D. Liles, Registration No. 28,320; Lynda E. Roesch, Registration No. 29,696; Martin J. Miller, Registration No. 35,953; Anne B. Pellot, Registration No. 37,781; Jackie A. Zurcher, Registration No. 42,251; John V. Harneyer, Registration No. 41,815; Scott N. Barker, Registration No. 42,292; Geoffrey L. Oberhaus, Registration No. 42,955; Joseph P. Mehrle, Registration No. 45,535; John P. Colbert, Registration No. 45,765; and Stephen S. Wentzler, Registration No. 46,403, c/o Dinsmore & Shohl, 1900 Cherasa Center, 255 East Fifth Street, Cincinnati, Ohio 45202 (513) 977-8200, my attorneys, with full power in each of them, of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

The undersigned hereby authorizes the above-named U.S. attorneys to accept and follow instructions from Pharmacia & Upjohn AB as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the undersigned and the aforementioned U.S. attorneys. In the event of a change in the firm or persons from whom instructions may be taken, the aforementioned U.S. attorneys will be so notified in writing by the undersigned.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Ib MENDEL-HARTVIG

Inventor's signature

Ib Mendel-Hartvig

29/8 2000
Date

Residence: Rabeniusvägen 28, S-756 55 Uppsala, Sweden

Citizenship: Sweden

Post Office Address: Rabeniusvägen 28, S-756 55 Uppsala, Sweden

0050731-10000

